Your session is about to expire
← Back to Search
EB05 for Hospitalized COVID-19 Patients
Study Summary
This trial is testing a potential new treatment, EB05, for people who have been hospitalized with COVID-19. The treatment is designed to target the initial step in the signalling pathways of these DAMPs in innate immunity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken immune system altering drugs recently, except for COVID-19 treatment or if I'm a transplant patient.I am currently pregnant or breastfeeding.I am 18 years old or older.You have a very severe case of COVID-19, graded at Level 6 or 7 on a scale of 1 to 9.You are allergic to EB05 or any of its ingredients.I am not currently in a clinical trial for immune system drugs.I was put on a breathing machine and then taken off it during this hospital stay.I've seen significant improvement in my condition before starting the new treatment.I had a cardiac arrest while in the hospital for COVID-19.I have been on a ventilator for more than 72 hours before getting the study drug.I am hospitalized due to COVID-19 related breathing issues.I have a lab-confirmed COVID-19 diagnosis.I have given or my legal representative has given consent for me to participate.
- Group 1: Stage 1
- Group 2: Stage 2
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the estimated sample size of this research endeavor?
"Indeed, clinicaltrials.gov's records verify that this study is currently enrolling participants. It was originally posted on November 25th 2020 and the latest update was made July 28th 2023. 644 people need to be admitted from 38 distinct medical sites."
Is there a high concentration of research centers in Canada conducting this study?
"This clinical trial can be accessed at 38 different medical facilities, including Providence Portland Medical Center in Portland, Vancouver Coastal Health in Vancouver and William Osler Health System in Brampton."
Is there any availability for participants to join this research study?
"Affirmative. This research project which was published on November 25th 2020 is presently recruiting from 38 different medical sites, aiming to enroll a total of 644 patients."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger